GLP-1 Drugs Linked to Fewer Relapses and Less Optic Neuritis in Multiple Sclerosis
A 12-year real-world U.S. study links GLP-1 drug use in people with MS to fewer steroid-treated relapses, less optic neuritis and fewer demyelinating events.
Summary
GLP-1 receptor agonists, drugs approved for diabetes and obesity, may also help people with multiple sclerosis. A large real-world U.S. analysis presented at the joint ECTRIMS/ACTRIMS meeting found that MS patients who used these drugs had lower rates of steroid-treated relapses (1.85% vs 4.84%), optic neuritis (1.46% vs 2.56%) and demyelinating events (3.48% vs 7.01%) over 12 years. They also had fewer gait problems, less fatigue and less depression. Results looked similar among patients taking the B-cell therapy ocrelizumab. Researchers think GLP-1 drugs may calm neuroinflammation and support neuron survival via the gut-brain axis. Because this is an observational study, it shows association, not proof of benefit. Past GLP-1 trials in Alzheimer's and Parkinson's disease have been mixed, so randomized trials in MS are needed before these drugs are used for it.
Detailed Summary
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that erodes mobility, vision and energy, and it is a major threat to healthy function across adult life. Current therapies reduce relapses but do not fully stop progression, so researchers are looking at drugs with neuroprotective and anti-inflammatory potential. GLP-1 receptor agonists, already widely used for diabetes and obesity, are now being investigated in this role.
A large real-world U.S. analysis presented by Mahsa Khayat-Khoei, MD, of the University of California Riverside at MSToronto2026 compared MS patients who used GLP-1 drugs with those who did not. Over 12 years, users had lower rates of acute steroid-treated relapses (1.85% vs 4.84%), optic neuritis (1.46% vs 2.56%) and demyelinating events (3.48% vs 7.01%). Gait abnormalities (10.46% vs 16.15%), fatigue (11.87% vs 17.55%) and depression (19.34% vs 26.38%) were also less common, all with P<0.00001.
In a subgroup treated with the B-cell therapy ocrelizumab, over a 10-year window, the pattern held. The largest relative risk reductions appeared for steroid-treated relapses (RR 5.52) and optic neuritis (RR 2.37).
The proposed biology centers on neuroinflammation and neuronal survival. Paul Edison, MD, PhD, of Imperial College London noted that GLP-1 drugs influence insulin signaling, mitochondrial resilience, vascular function and inflammation, giving a credible rationale. Animal models of Alzheimer's, Parkinson's, MS and stroke support this idea. Clinical results elsewhere are mixed: oral semaglutide failed to slow Alzheimer's in the EVOKE trials, liraglutide showed some cognitive and brain volume benefits in ELAD, and exenatide's Parkinson's benefit did not hold in phase III.
Practically, people with MS should not start a GLP-1 drug for relapse prevention on this evidence alone. Those who already have a metabolic indication may have extra reasons to discuss treatment with their neurologist.
The main caveat is design. Observational data can be distorted by confounding, such as differences in health, weight, access to care or treatment choices between users and nonusers. Randomized trials must confirm whether GLP-1 drugs truly protect the nervous system in MS.
Key Findings
- GLP-1 users with MS had fewer steroid-treated relapses over 12 years: 1.85% versus 4.84% in nonusers.
- Optic neuritis (1.46% vs 2.56%) and demyelinating events (3.48% vs 7.01%) were also lower with GLP-1 exposure.
- Gait abnormalities, fatigue and depression were less frequent among GLP-1 users, supporting possible functional benefits.
- Patients on ocrelizumab showed similar patterns, with RR 5.52 for steroid-treated relapses.
- Findings are observational; trials of semaglutide in Alzheimer's and exenatide in Parkinson's show GLP-1 neuroprotection remains unproven.
Methodology
This is a news report on a conference presentation (ECTRIMS/ACTRIMS) of a retrospective real-world U.S. cohort analysis, with commentary from an independent expert. MedPage Today is a reputable medical news outlet, but the data are presented orally and are likely not yet peer reviewed. The evidence is observational.
Study Limitations
Observational data cannot rule out confounding or reverse causation, and details on cohort selection, adjustment methods and specific GLP-1 agents are not given in the excerpt. The article is truncated, and the full abstract or peer-reviewed publication should be checked. Randomized controlled trials are needed to confirm causality.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: